[Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne
U K
UK
Department of Neurology, University of Turku, Finland.
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008090:Lisuride / Q000008:administration & dosage / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D010479:Pergolide / Q000008:administration & dosage / Q000627:therapeutic use; D012642:Selegiline / Q000008:administration & dosage / Q000627:therapeutic use
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D008996:Monoamine Oxidase Inhibitors; D010479:Pergolide; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; D008090:Lisuride
Optimización del tratamiento de la enfermedad de Parkinson con agonistas de dopamina.